Evidence map›Paper›PMID 27305912›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.

K Kalinsky, T Zheng, H Hibshoosh, X Du, P Mundi, J Yang, S Refice, S M Feldman, B Taback, E Connolly and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00930579 (Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00930579 phase2completednot on this map

Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation

TypeinterventionalSponsorColumbia UniversityRan2009 to 2017Enrolled35ConditionsBreast CancerArmsMetformin
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Trial
  2. Review
  3. RETRACTED: Metformin and Breast Cancer: Where Are We Now?International journal of molecular sciences · 2022
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Obesity and Cancer Mechanisms: Cancer Metabolism.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

K KalinskyDepartment of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA. kk2693@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-1583-3553
T ZhengDepartment of Statistics, Columbia University, New York, USA.
H HibshooshHerbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.
X DuHerbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.
P MundiDepartment of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.
J YangDepartment of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.
S ReficeDepartment of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.
S M FeldmanHerbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.
B TabackHerbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.
E ConnollyHerbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Avenue, 10th Floor, Room 1069, New York, USA.
K D CrewDepartment of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.
M A MaurerDepartment of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.
D L HershmanDepartment of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA.
Columbia University Irving Medical Center · USColumbia University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Clinical and Translational Science AwardKL2TR000081 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$3.3M
Pre-Surgical trial of Metformin and Atorvastatin in Operable Breast CancerR03CA186931 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KALINSKY, KEVIN MICHAEL · 2014 to 2015
$150k
NCATS NIH HHS KL2 TR000081NCI NIH HHS P30 CA016672NCI NIH HHS R03 CA186931
6 · The paper itself

Abstract

purposeReverse Phase Protein Array (RPPA) is a high-throughput antibody-based technique to assess cellular protein activity. The goal of this study was to assess protein marker changes by RPPA in tumor tissue from a pre-surgical metformin trial in women with operable breast cancer (BC).

methodsIn an open-label trial, metformin 1500-mg PO daily was administered prior to resection in 35 non-diabetic patients with stage 0-III BC, body mass index ≥25 kg/m

resultsAfter adjusting for multiple comparisons in the 32 tumors from metformin-treated patients vs. 34 untreated historical controls, 11 proteins were significantly different between cases vs. CONTROLS: increases in Raptor, C-Raf, Cyclin B1, Cyclin D1, TRFC, and Syk; and reductions in pMAPK

conclusionsThese results suggest that metformin modulates apoptosis/cell cycle, cell signaling, and invasion/motility. These findings should be assessed in larger metformin trials. If confirmed, associations between these changes and BC clinical outcome should be evaluated. CLINICALTRIALS. GOV IDENTIFIER: NCT00930579.

Indexed as

ApoptosisBiomarkers, TumorBlotting, WesternBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCell CycleCohort StudiesFemaleFollow-Up StudiesHumansHypoglycemic AgentsImmunoenzyme TechniquesMetforminNeoplasm InvasivenessNeoplasm StagingPrognosisBiomarkers, TumorHypoglycemic AgentsMetforminBreast CancerCyclin D1ImmunohistochemistryMetforminPre-surgicalReverse Phase Protein Array

Identifiers

PMID27305912
PMCPMC7028354
OpenAlexW2421664521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.